🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Featured today by MSK Library: Bioinformatically Expanded #NextGenSequencing Analysis Optimizes ID of Therapeutically Relevant MET Copy # Alterations in >50K Tumors dx.doi.org/10.1158/1078-0… MSK Department of Pathology & Laboratory Medicine Memorial Sloan Kettering Biostatistics Service Weill Cornell Medicine Pathology Soo-Ryum (Stew) Yang MD Noura Choudhury, MD Ryan N. Ptashkin Axel Martin

Report on resistance to 1L osimertinib in 327pts treated at MSKCC JTO & JTO CRR. Atypical #EGFR mPFS 5.8m, concurrent TP53/RB1 mPFS 10.5m. 95pts had post-progression biopsy; resistance mechanism seen in 52% (most common were #MET, #SCLC, EGFR amp). jto.org/article/S1556-…

‼️ #ASCO23 simultaneous publication in #JCO by Gregory Riely et al: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Metastatic BRAFV600-Mutant #NSCLC fal.cn/3yNHH

Excited to share our case report on a rare case of cardiac angiosarcoma presenting with constrictive physiology. 🔑: keep a broad differential to ensure rare diseases are considered. (Harsimran Sachdeva Singh, Jim Cheung, Weill Cornell Cardiology Fellowship, Weill Cornell Medicine Cardiothoracic Surgery). academic.oup.com/ehjcr/article/…

Great collaborative effort with Gʀᴇɢᴏʀʏ Rɪᴇʟʏ Noura Choudhury, MD and Sai-Hong Ignatius Ou Kathryn F. Mileham, MD, FACP, FASCO Suresh S. Ramalingam, MD, FASCO groups. Our results suggest there should be less incentive to continue full-dose lorlatinib if toxicities are encountered. JTO & JTO CRR

Proud of Adam Vohra’s important work on hospital load imbalance during the pandemic, now out in Health Affairs!

Great to see this out and thanks to many collaborators and contributors to this work!

🔥Our latest publication just out in Journal of Clinical Oncology 🔍 In an analysis of >28k pts, pancreatic acinar cell carcinoma was the cancer type with the highest prevalence of gBRCA2 and HRD features 👉 Relevance for both therapeutic and screening strategies ascopubs.org/doi/10.1200/JC…

Stop by poster 698P #ESMO23 for a look at HPN328, the DLL3 T-cell engager you don’t want to miss!

Grateful to LUNGevity Foundation (and mentorship from Charlie Rudin and the entire MSK TOS team) for this Career Development award aimed at improving outcomes for patients with SCLC!

Super proud of Melina Marmarelis as she leads the session on thymic malignancies w/ Noura Choudhury, MD #TTLC24 IASLC Lecia Sequist, MD, MPH Joel W. Neal, MD, PhD Karen Kelly

Enjoyed presenting our work on genomics of FGFR-altered biliary tract cancers at APPLE 2024 meeting in Honolulu - thanks Noura Choudhury, MD Alison Schram Alexander Drilon MD and Jim Harding for the collaboration and Ghassan Abou-Alfa for organizing!

1 Hot off the press from team Memorial Sloan Kettering Cancer Center in Cancer Discovery! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇

Currently at #WCLC24, Jacob sands, Enriqueta Felip, @Dingemans_AnneM, Luis Paz-Ares, Noura Choudhury, MD, Ticiana Batista (Leal) and others are presenting the topic: DLL3 Targeting BiTE Therapies in #SCLC. #LCSM #IASLC50 #LungCancer

MK-6070 (DLL3 T cell engager) at doses at least 1.215 mg showed antitumor activity in SCLC. Confirmed ORR = 36% in pts with h/o brain met (lower ORR of 18% in pts with no history of brain met, ?mechanism/explanation) Another active T cell engager for SCLC. #WCLC24

Really engaging discussion on #SCLC at #MaTOS24 with Drs. Paul Bunn Noura Choudhury, MD Ticiana Batista (Leal) Christine Hann Puneeth Iyengar Misty Dawn Shields

Great work by Jake Doll and team showing the reliability and feasibility of intravascular imaging as a performance measure. Dmitriy N. Feldman, MD and I share our thoughts in CircInterventions on the positives / negatives of using IVI as a metric. Link: ahajournals.org/doi/10.1161/CI…

Phase 1/2 trial of LSD1 inhibitor iadademstat + immunotherapy maintenance in first-line ES-SCLC. Great to see ES-SCLC trial design that minimizes barriers for patients to participate. Noura Choudhury, MD UChicagoCancerCenter SmallCellSMASHERS #SCLC25

#TexasLung25 Day 2: Panel discussing sequencing of drugs in 2nd line ES-SCLC. 👉🏽Now that tarlatamab has OS, what is the best sequence of therapy 👉🏽Importance of patient selection & support 👉🏽New ADCs and immuno combinations in horizon #lcsm Lauren Averett Byers, MD Bingnan Zhang

Team #SCLC IASLC - superstar group of speakers and panelists TLC Conference Misty Dawn Shields Bingnan Zhang Ticiana Batista (Leal) Noura Choudhury, MD , Dr Pam Samson (and Jacob sands - who promises to wear a powder blue suit next year to match us)